Singapore: Qualyst Transporter Solutions entered an alliance with GenoMembrane, Kanagawa, Japan, to make available its B-Clear Technology to customers in Japan.

The initial offering will focus on supplying B-Clear kits of rat and human hepatocytes, both plated with Transporter certified hepatocytes. In addition, contract services projects can be facilitated through GenoMembrane. The alliance will facilitate access to B-Clear technology in Japan, which can be used to predict the biliary excretion of drugs, evaluate clinically relevant drug interactions, determine the cholestatic potential of drugs, and estimate their intracellular concentration.

"B-Clear human kits for Japan use cryopreserved human hepatocytes that have been certified for transporter function (uptake and efflux), providing the customer with clinically relevant data, and a high level of reproducibility from experiment to experiment." said Dr Christopher Black, CEO, Qualyst Transporter Solutions.

Qualyst Transporter Solutions only uses Transporter certified hepatocytes in its kits and services to examine the potential for in vivo relevant transporter-based drug interactions. The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning cell system that has been certified for transporter function. "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees that the results are in vivo-relevant," said Dr Kenneth Brouwer, CSO, Qualyst Transporter Solutions.

"We are excited that we can now offer B-Clear kits with both rat and human hepatocytes to our Japanese customers, as well as an opportunity to offer other relevant research services conducted by Qualyst Transporter Solutions," said Mr Satoshi Senda, CEO, GenoMembrane.